Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer

DOI10.1016/j.jtbi.2018.09.022zbMath1406.92288OpenAlexW2889627012WikidataQ64121870 ScholiaQ64121870MaRDI QIDQ1712868

Joel S. Brown, Jessica J. Cunningham, Robert A. Gatenby, Kateřina Staňková

Publication date: 1 February 2019

Published in: Journal of Theoretical Biology (Search for Journal in Brave)

Full work available at URL: https://zenodo.org/record/3552683

zbMATH Keywords

optimal controlevolutionary game theoryeco-evolutionary dynamicscompetitive releaseadaptive therapymetastatic castrate-resistant prostate cancer

Mathematics Subject Classification ID

Applications of optimal control and differential games (49N90) Medical applications (general) (92C50) Population dynamics (general) (92D25) Evolutionary games (91A22)

Related Items (13)

The contribution of evolutionary game theory to understanding and treating cancer ⋮ Modeling the synergistic properties of drugs in hormonal treatment for prostate cancer ⋮ Including blood vasculature into a game-theoretic model of cancer dynamics ⋮ Towards optimal control of amyloid fibrillation ⋮ Modelling bistable tumour population dynamics to design effective treatment strategies ⋮ Designing experimental conditions to use the Lotka-Volterra model to infer tumor cell line interaction types ⋮ Tumor containment: a more general mathematical analysis ⋮ Game theory for managing evolving systems: challenges and opportunities of including vector-valued strategies and life-history traits ⋮ An optimization method for treating solid tumors with combined therapy using the great deluge algorithm ⋮ An evolutionary dynamics model for metastatic tumour growth based on public goods games ⋮ Practically scheduling hormone therapy for prostate cancer using a mathematical model ⋮ Do mechanisms matter? Comparing cancer treatment strategies across mathematical models and outcome objectives ⋮ Dynamics of a non-smooth model of prostate cancer with intermittent androgen deprivation therapy

Cites Work

• Unnamed Item
• Unnamed Item
• Unnamed Item
• Optimal control in a model of dendritic cell transfection cancer immunotherapy
• Optimal control for selected cancer chemotherapy ODE models: a view on the potential of optimal schedules and choice of objective function
• Optimal response to chemotherapy for a mathematical model of tumor-immune dynamics
• Optimal control for resistance and suboptimal response in CML
• Ability of intermittent androgen suppression to selectively create a non-trivial periodic orbit for a type of prostate cancer patients
• The influence of PK/PD on the structure of optimal controls in cancer chemotherapy models
• Analysis and optimization of drug resistant an phase-specific cancer chemotherapy models
• Optimal control for a cancer chemotherapy problem with general growth and loss functions
• Optimal control analysis in the chemotherapy of IgG multiple myeloma
• Necessary optimality conditions for a singular surface in the form of synthesis
• Optimal control for a stochastic model of cancer chemotherapy
• A two-phenotype model of immune evasion by cancer cells
• Spatial vs. non-spatial eco-evolutionary dynamics in a tumor growth model
• Controlling a model for bone marrow dynamics in cancer chemotherapy
• Maximum tolerated dose versus metronomic scheduling in the treatment of metastatic cancers
• Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis
• Some optimal control problems in cancer chemotherapy with a toxicity limit
• Optimization of an \textit{in vitro} chemotherapy to avoid resistant tumours
• Cancer immunotherapy, mathematical modeling and optimal control
• Optimal treatment strategy for a tumor model under immune suppression
• Determination of the optimal therapeutic protocols in cancer immunotherapy
• Optimal control of treatment in a mathematical model of chronic myelogenous leukemia
• Optimal control in some cancer chemotherapy problems

This page was built for publication: Optimal control to develop therapeutic strategies for metastatic castrate resistant prostate cancer